A Case of Acquired Methemoglobinemia Following Sentinel Lymph Node Dye With Patent Blue V.

Methemoglobinemia is a rare but potentially life-threatening condition in which hemoglobin is oxidized, impairing the oxygen-carrying capacity. While congenital forms exist, acquired methemoglobinemia can occur in perioperative settings, especially following exposure to oxidizing agents such as dyes used in sentinel lymph node biopsy (SLNB). Patent Blue V, a synthetic aniline dye commonly used for SLNB, has been associated with rare but serious adverse effects, including methemoglobinemia.

Methaemoglobinaemia in neonates with acute gastroenteritis: lethal, but curable.

Methaemoglobinaemia is a rare factor that can lead to cyanosis. The predominant cause of acquired methaemoglobinaemia is commonly attributed to anaesthetic agents. This case series presents three instances of acquired methaemoglobinaemia resulting from acute gastroenteritis caused by formula feeds.

Why so blue? A novel presentation of methaemoglobinaemia secondary to an inhaled occupational nitric acid exposure.

Introduction: Nitric and hydrofluoric acids are commonly used in the commercial cleaning industry. We are unaware of reports of nitric acid inhalation forming methaemoglobin. Additionally, methaemoglobinaemia and treatment with methylthioninium chloride (methylene blue) may precipitate clinical uncertainty due to similar wavelengths of absorbance in pulse oximetry.

Risky Remedy: Rasburicase-Induced Methemoglobinemia in Tumor Lysis Syndrome Complicated by G6PD Deficiency.

Tumor lysis syndrome (TLS) is a critical oncologic emergency characterized by metabolic disturbances resulting from rapid cancer cell lysis. Rasburicase, a recombinant urate oxidase, is the primary treatment for hyperuricemia in TLS but poses a risk for methemoglobinemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. We present the case of a 59-year-old male with diffuse large B-cell lymphoma (DLBCL) who developed spontaneous TLS.

Occult Methemoglobinemia in a Medically-Complex 7-Year-Old Child and the Opportunity for Pharmacist Intervention in Pediatric Emergency Medicine.

Methemoglobinemia is a rare, yet life-threatening disorder that occurs due to an accumulation of methemoglobin in the blood. The clinical presentation often includes dyspnea, cyanosis, and hypoxemia that shows little improvement with the administration of supplemental oxygen. The US Food and Drug Administration (FDA) warns against the administration of benzocaine to those younger than 2 years of age and urges manufacturers to add a statement regarding the possible development of methemoglobinemia to the packaging of any products containing this ingredient.

Deadly shades of green: A cautionary tale of an organic biopesticide poisoning.

Introduction: Methemoglobinemia is a potentially life-threatening condition characterized by the reduced oxygen-carrying capacity of hemoglobin. With the increasing popularity of natural and herbal biopesticides, there is a growing risk of exposure to substances that can induce this dyshemoglobinemia. This case report highlights the importance of recognizing and promptly treating methemoglobinemia in the context of biopesticide exposure, a concern relevant to various healthcare professionals.